KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Nektar Therapeutics (NKTR) over the last 16 years, with Dec 2024 value amounting to $10.7 million.

  • Nektar Therapeutics' Change in Accured Expenses fell 206.92% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.6 million, marking a year-over-year decrease of 227.42%. This contributed to the annual value of $10.7 million for FY2024, which is 162.17% up from last year.
  • Nektar Therapeutics' Change in Accured Expenses amounted to $10.7 million in FY2024, which was up 162.17% from -$17.3 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Change in Accured Expenses ranged from a high of $10.7 million in FY2024 and a low of -$22.9 million during FY2021.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$17.3 million (2023), whereas its average is -$8.8 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Change in Accured Expenses crashed by 365.22% in 2021, and later soared by 162.17% in 2024.
  • Nektar Therapeutics' Change in Accured Expenses (Yearly) stood at $8.6 million in 2020, then slumped by 365.22% to -$22.9 million in 2021, then grew by 12.99% to -$19.9 million in 2022, then grew by 13.45% to -$17.3 million in 2023, then spiked by 162.17% to $10.7 million in 2024.